Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
0.8570
-0.0805 (-8.59%)
At close: Oct 13, 2026, 4:00 PM EDT
0.8738
+0.0168 (1.96%)
After-hours: Oct 13, 2026, 7:59 PM EDT
Compass Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
154.34M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 850.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 50.94M |
| Precision BioSciences | 45.06M |
| MediWound | 11.86M |
| Oramed Pharmaceuticals | 2.00M |
| Veraxa Biotech AG | 29.54K |
CMPX News
- 20 days ago - Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum - TheFly
- 20 days ago - Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig - TheFly
- 20 days ago - Compass Therapeutics price target lowered to $4 from $8 at Guggenheim - TheFly
- 20 days ago - Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright - TheFly
- 20 days ago - Compass Therapeutics price target lowered to $4 from $10 at Citizens - TheFly
- 21 days ago - Compass Therapeutics downgraded to Neutral from Outperform at Wedbush - TheFly
- 21 days ago - Compass Therapeutics downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 21 days ago - Compass Therapeutics says FDA requests new trial for tovecimig - TheFly